Immune checkpoint inhibitors have improved outcomes for many cancer patients, but they can also trigger inflammatory side effects. A new study published in ACR Open reports that rheumatic complications from these drugs are more serious than previously recognized.
The researchers found that rheumatic immune-related adverse events (rh-irAEs) are usually moderate or severe. In more than a third of cases, the events led to permanent discontinuation of the immune checkpoint inhibitor, a decision that could affect cancer treatment outcomes.
These findings highlight the need for careful monitoring and management of rheumatic symptoms in patients receiving immune checkpoint inhibitors, particularly because such reactions may be more frequent and burdensome than earlier data suggested.